Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.

Robson EJ, Ghatage P.

Expert Opin Investig Drugs. 2011 Feb;20(2):297-304. doi: 10.1517/13543784.2011.549125. Epub 2011 Jan 6. Review.

PMID:
21210755
2.

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS.

J Clin Oncol. 2009 Jul 20;27(21):3557-65. doi: 10.1200/JCO.2008.19.6683. Epub 2009 Jun 22.

PMID:
19546406
3.

Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).

Marchetti C, Gasparri ML, Ruscito I, Palaia I, Perniola G, Carrone A, Farooqi AA, Pecorini F, Muzii L, Panici PB.

Crit Rev Oncol Hematol. 2015 Jun;94(3):302-10. doi: 10.1016/j.critrevonc.2015.02.001. Epub 2015 Mar 4. Review.

PMID:
25783620
4.
5.

Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.

Al Wadi K, Ghatage P.

Expert Opin Pharmacother. 2016;17(6):853-60. doi: 10.1517/14656566.2016.1161027. Epub 2016 Mar 21. Review.

PMID:
26933765
6.

Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.

Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, Le N, LoRusso P.

Clin Cancer Res. 2010 Jun 1;16(11):3044-56. doi: 10.1158/1078-0432.CCR-09-3368. Epub 2010 May 25.

7.

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH Jr, Brown JV 3rd, Covens A, Nagarkar RV, Davy M, Leath CA 3rd, Nguyen H, Stepan DE, Weinreich DM, Tassoudji M, Sun YN, Vergote IB.

J Clin Oncol. 2012 Feb 1;30(4):362-71. doi: 10.1200/JCO.2010.34.3178. Epub 2011 Dec 19.

PMID:
22184370
8.

Targeting angiopoietin-2 signaling in cancer therapy.

Eroglu Z, Stein CA, Pal SK.

Expert Opin Investig Drugs. 2013 Jul;22(7):813-25. doi: 10.1517/13543784.2013.793306. Epub 2013 Apr 27. Review.

PMID:
23621441
9.

Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.

Weeraratne DK, Lofgren J, Dinnogen S, Swanson SJ, Zhong ZD.

J Immunol Methods. 2013 Oct 31;396(1-2):44-55. doi: 10.1016/j.jim.2013.07.010. Epub 2013 Aug 6.

PMID:
23933325
10.

Novel therapies, including enzastaurin, in the treatment of ovarian cancer.

Vergote I.

Expert Opin Investig Drugs. 2014 May;23(5):579-98. doi: 10.1517/13543784.2014.900542. Epub 2014 Mar 22. Review.

PMID:
24654681
11.

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.

Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R.

Gynecol Oncol. 2015 Sep;138(3):513-8. doi: 10.1016/j.ygyno.2015.07.006. Epub 2015 Jul 11.

12.

Angiogenesis: a promising therapeutic target for ovarian cancer.

Bamias A, Pignata S, Pujade-Lauraine E.

Crit Rev Oncol Hematol. 2012 Dec;84(3):314-26. doi: 10.1016/j.critrevonc.2012.04.002. Epub 2012 May 8. Review.

PMID:
22575381
13.

Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.

Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G.

Cancer Res. 2003 Jun 15;63(12):3403-12.

14.

Emerging VEGF-receptor inhibitors for colorectal cancer.

Martinelli E, Troiani T, Morgillo F, Orditura M, De Vita F, Belli G, Ciardiello F.

Expert Opin Emerg Drugs. 2013 Mar;18(1):25-37. doi: 10.1517/14728214.2013.749856. Epub 2012 Dec 6. Review.

PMID:
23216053
15.

Experience with bevacizumab in the management of epithelial ovarian cancer.

Burger RA.

J Clin Oncol. 2007 Jul 10;25(20):2902-8. Review.

PMID:
17617521
16.

Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer?

Dizon DS.

Am J Clin Oncol. 2013 Oct;36(5):519-25. doi: 10.1097/COC.0b013e318216e699. Review.

PMID:
21552100
17.

The emerging role of anti-angiogenic therapy in ovarian cancer (review).

Conteduca V, Kopf B, Burgio SL, Bianchi E, Amadori D, De Giorgi U.

Int J Oncol. 2014 May;44(5):1417-24. doi: 10.3892/ijo.2014.2334. Epub 2014 Mar 10. Review.

PMID:
24626312
18.

Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.

Sharma T, Dhingra R, Singh S, Sharma S, Tomar P, Malhotra M, Bhardwaj TR.

Mini Rev Med Chem. 2013 Apr;13(4):530-40. Review.

PMID:
23317499
19.

AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases.

Oliner JD, Bready J, Nguyen L, Estrada J, Hurh E, Ma H, Pretorius J, Fanslow W, Nork TM, Leedle RA, Kaufman S, Coxon A.

Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2170-80. doi: 10.1167/iovs.11-7381.

PMID:
22410553
20.

Targeting angiogenesis in ovarian cancer.

Schmitt J, Matei D.

Cancer Treat Rev. 2012 Jun;38(4):272-83. doi: 10.1016/j.ctrv.2011.06.004. Epub 2011 Jul 18. Review.

PMID:
21764518

Supplemental Content

Support Center